. Author manuscript; available in PMC: 2009 Nov 30.

Published in final edited form as: Expert Rev Anticancer Ther. 2009 Jan;9(1):51–60. doi: 10.1586/14737140.9.1.51

Table 4.

Average annual rates of uterine disease and hysterectomy by treatment group in the NSABP STAR trial.

Type of uterine event	Events (n)		Rate per 1000^* individuals			Risk ratio^§	95% confidence interval
Type of uterine event	Tamoxifen	Raloxifene	Tamoxifen	Raloxifene	Difference^‡	Risk ratio^§	95% confidence interval
Invasive cancer	36	23	1.99	1.25	0.75	0.62	0.35–1.08
Hyperplasia^¶	84	14	4.69	0.76	3.93	0.16	0.09–0.29
Without atypia	72	13	4.02	0.71	3.31	0.18	0.09–0.32
With atypia	12	1	0.67	0.05	0.62	0.08	0.00–0.55
Hysterectomy during follow-up^¶	221	87	12.24	4.72	7.52	0.39	0.30–0.50

Women at risk were those with an intact uterus at entry.

^‡

Rate in the tamoxifen group minus rate in the raloxifene group.

^§

Risk ratio for women in the raloxifene group compared with women in the tamoxifen group.

^¶

Among women not diagnosed with uterine cancer.

NSABP: National Surgical Adjuvant Breast and Bowel Project; STAR: Study of Tamoxifen and Raloxifene.